Insider buying last 90 days
No open-market insider purchases were filed for AUPH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AUPH insider filing, plotted on the chart in Gekko.Open AUPH in Gekko
NASDAQ: AUPH
Aurinia Pharmaceuticals (AUPH) Stock Analysis & Forecast
Oct 12 close
$16.55−0.10 (−0.6%)
Gekko Brief
AI summaryOct 12 closeThis week's coverage centers on Aurinia Pharmaceuticals' second-quarter results and the lead-up to its next earnings report. The company reported a 74% increase in second-quarter net income to $37.40 million, with total revenue up 19% to $83.20 million, driven by LUPKYNIS sales, and maintained its 2026 revenue guidance. Separately, reports note that new CEO Kevin Tang, who took over in March and has replaced most of the executive team with leaders from his venture capital firm, is reportedly planning an early exit from the company's Montgomery County lease.
AUPH closed at $16.55, down 0.6%, sitting above both its 50-day average of $16.12 and 200-day average of $15.56, with the shorter average above the longer one. The GekkoIndex reads 55.5, placing the stock in the Neutral zone, with a five-point change of -7.9. Price sits 1.4% below Gekko Fair Value of $16.79.
The next earnings date falls on 3 November, 22 days away and before the open, which is inside a typical 20-trading-day holding window; the prior report on 6 August beat estimates, with EPS of $0.28 against a $0.24 estimate and a 4.3% reaction, against an average absolute reaction of 6.4% across the last eight quarters, seven of which beat estimates. Seasonality from this point has averaged 14.4% over the next 20 trading days across 5 years, rising in 4 of them. No insider, Congress or unusual options activity appears in the current window.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Aurinia Pharmaceuticals price vs fair value
Close $16.55200-day averageGekko Fair Value $16.79
Aurinia Pharmaceuticals quick facts
- Market cap
- $2.13B
- P/E ratio
- 7.1
- Forward P/E
- 11.8
- EPS, TTM
- $2.28
- Revenue, TTM
- $311.5M
- Profit margin
- 100.8%
- Dividend yield
- —
- Beta
- 1.61
- Volume
- 654,764 avg 829,256
- 1-year return
- +42.4%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±8%
- 50-day average
- $16.12
- 200-day average
- $15.56
- Next earnings
- Nov 3 before open
- Shares outstanding
- 133.1M
Aurinia Pharmaceuticals swing-trade checklist
Aurinia Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $16.55 is above the 50-day ($16.12) and 200-day ($15.56) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.5, Neutral
Reading 55.5 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
1.4% below
Price is within 5% of Gekko Fair Value (1.4% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+14.4% on average
From this point in the calendar, the next 20 trading days averaged +14.4% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Aurinia Pharmaceuticals stock chart and price history
Aurinia Pharmaceuticals closed at $16.55 on Oct 12, 2026, +42.4% over the past year, inside a 52-week range of $10.90 to $19.25.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.8%
- 3 months
- +3.6%
- 6 months
- +3.1%
- 1 year
- +42.4%
The full AUPH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AUPH in Gekko
Follow Aurinia Pharmaceuticals through every session
Put AUPH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AUPH in GekkoFree for 7 days. No credit card required.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals develops and markets medical treatments aimed at conditions that lack sufficient existing options. It has reached the stage of selling its own products rather than only researching them, with patients reached both within the United States and in other countries. The company is most recognized for LUPKYNIS, a therapy approved for adult patients dealing with active lupus nephritis.
Alongside its own commercial efforts, Aurinia works with Otsuka Pharmaceutical Co., Ltd. through a licensing and collaboration arrangement, pairing its treatment development with a partner relationship that extends its reach.
The company runs its main office out of Victoria, Canada. Its shares are listed on the NASDAQ under the ticker AUPH.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- auriniapharma.com
Aurinia Pharmaceuticals GekkoIndex: the smart money zone
Aurinia Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.5, in the Neutral zone, down 7.9 points over five sessions.
55.5Neutral
Down 7.9 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 12 | +1.7% | −5.1% | ||
| Accumulation | 198 | +1.2% | +4.3% | ||
| Neutral (current zone) | 423 | +0.6% | +2.8% | ||
| Distribution | 41 | 0.0% | +3.7% | ||
| Selling | 8 | Too few readings yet | |||
Average AUPH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the AUPH price, zone by zone.Track AUPH in Gekko
Is Aurinia Pharmaceuticals stock overvalued? Gekko Fair Value
Aurinia Pharmaceuticals trades 1.4% below Gekko Fair Value of $16.79, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Aurinia Pharmaceuticals shares are worth, recalculated every trading day.
$16.79
Gekko Fair Value, Oct 10, 2026
1.4% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open AUPH in Gekko
Aurinia Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Aurinia Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AUPH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AUPH, plotted on the chart in Gekko.Open AUPH in Gekko
Buybacks
Aurinia Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $38.37M
- As a share of market cap
- 1.80%
- Trailing four quarters
- $84.87M
From company filings.
Aurinia Pharmaceuticals earnings: next date and track record
Aurinia Pharmaceuticals reports on Nov 3, 2026, before the open (22 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 22 days away
- EPS estimate
- $0.22
- Revenue estimate
- $83.61M
7 of 8reports beat the EPS estimate
±6.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.28 est $0.24 | $83.22M est $80.45M | +4.3% |
| May 7, 2026 | $0.25 est $0.16 | $77.71M est $76.98M | −6.3% |
| Feb 26, 2026 | $1.53 est $0.22 | $77.11M est $74.70M | −1.8% |
| Nov 4, 2025 | $0.23 est $0.16 | $73.47M est $74.70M | +9.7% |
| Jul 31, 2025 | $0.16 est $0.17 | $70.01M est $67.70M | +15.9% |
| May 12, 2025 | $0.16 est $0.10 | $62.47M est $64.64M | −2.2% |
| Feb 27, 2025 | $0.01 est −$0.02 | $59.87M est $61.83M | 0.0% |
| Nov 7, 2024 | $0.10 est $0.01 | $67.77M est $65.06M | +10.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Aurinia Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Aurinia Pharmaceuticals is $17.86, +7.9% from the last close, from 3 firms rating the stock in the last 90 days.
$17.86consensus 12-month target, +7.9% from the last close
Now $16.55Avg $17.86
Low $16High $21
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 20 | Bloom Burton | $21 | +26.9% |
| Aug 19 | TD Cowen | $17 | +2.7% |
| Aug 10 | Bloom Burton | $15 | −9.4% |
| Aug 7 | RBC Capital | $16 | −3.3% |
| Aug 6 | TD Cowen | $17 | +2.7% |
+2.8%average 20-day move after past Neutral readings
+14.4%average move over the next 20 trading days in the last 5 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Aurinia Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Aurinia Pharmaceuticals averaged +14.4% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.9% | 3 of 5 |
| Next 10 trading days | +9.5% | 4 of 5 |
| Next 15 trading days | +18.2% | 4 of 5 |
| Next 20 trading days | +14.4% | 4 of 5 |
| Next 30 trading days | +7.1% | 3 of 5 |
For scale, AUPH’s typical 20-trading-day move in either direction is about 8%.
Aurinia Pharmaceuticals market cap and key statistics
Aurinia Pharmaceuticals’s market cap is $2.13B, with a P/E ratio of 7.1 and revenue of $311.5M over the last twelve months.
Valuation
- Market cap
- $2.13B
- P/E ratio
- 7.1
- Forward P/E
- 11.8
- EPS, TTM
- $2.28
- Gekko Fair Value
- $16.79
Trading
- Volume
- 654,764
- Avg volume, 20 days
- 829,256
- 52-week high
- $19.25
- 52-week low
- $10.90
- Shares outstanding
- 133.1M
Financials
- Revenue, TTM
- $311.5M
- Profit margin
- 100.8%
- Return on equity
- 66.1%
- Quarterly earnings growth, YoY
- +75.5%
Risk and income
- Beta
- 1.61
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±8%
Aurinia Pharmaceuticals stock news this week
Coverage of Aurinia Pharmaceuticals this week reads positive: 2 positive, 0 neutral and 1 negative headlines.
- Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)Defense World, Oct 12
- Aurinia Pharmaceuticals plots early exit from Montgomery County lease following leadership overhaulThe Business Journals, Oct 8
- Aurinia Pharmaceuticals stock heads toward its November 3 reportAD HOC NEWS, Oct 8
- Aurinia reports second-quarter profit growth: what it means for Aurinia Pharmaceuticals stockAD HOC NEWS, Oct 7
Aurinia Pharmaceuticals peers
Aurinia Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Aurinia Pharmaceuticals stock FAQ
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $2.13B at the Oct 12, 2026 close of $16.55, with 133.1M shares outstanding. The shares trade on a P/E ratio of 7.1.
What is the Aurinia Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Aurinia Pharmaceuticals is $17.86, +7.9% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Aurinia Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Aurinia Pharmaceuticals is about fair value: the Oct 12, 2026 close of $16.55 is 1.4% below Gekko Fair Value of $16.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Aurinia Pharmaceuticals report earnings next?
Aurinia Pharmaceuticals is expected to report on Nov 3, 2026, before the market opens (22 days away). Analysts expect earnings of $0.22 per share on revenue of $83.61M. Aurinia Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 6.4% on average across the report.
What is Aurinia Pharmaceuticals’s 52-week high and low?
Aurinia Pharmaceuticals’s 52-week high is $19.25 and its 52-week low is $10.90; it closed at $16.55 on Oct 12, 2026, +42.4% over the past year. Over the last five years the shares peaked at $33.97 on Nov 3, 2021.
Is Aurinia Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Aurinia Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.